NASDAQ:CVKD Cadrenal Therapeutics (CVKD) Stock Price, News & Analysis $0.45 +0.01 (+2.29%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$0.43▼$0.4650-Day Range$0.40▼$0.5152-Week Range$0.36▼$2.17Volume49,007 shsAverage Volume258,820 shsMarket Capitalization$7.15 millionP/E RatioN/ADividend YieldN/APrice Target$3.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Cadrenal Therapeutics alerts: Email Address Cadrenal Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside683.3% Upside$3.50 Price TargetShort InterestHealthy0.34% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.43Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.36) to ($0.34) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.58 out of 5 stars 3.5 Analyst's Opinion Consensus RatingCadrenal Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCadrenal Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Cadrenal Therapeutics' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.34% of the float of Cadrenal Therapeutics has been sold short.Short Interest Ratio / Days to CoverCadrenal Therapeutics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cadrenal Therapeutics has recently decreased by 41.52%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCadrenal Therapeutics does not currently pay a dividend.Dividend GrowthCadrenal Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CVKD. Previous Next 3.0 News and Social Media Coverage News SentimentCadrenal Therapeutics has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Cadrenal Therapeutics this week, compared to 0 articles on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cadrenal Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders48.62% of the stock of Cadrenal Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 7.92% of the stock of Cadrenal Therapeutics is held by institutions.Read more about Cadrenal Therapeutics' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Cadrenal Therapeutics are expected to grow in the coming year, from ($0.36) to ($0.34) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cadrenal Therapeutics is -1.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cadrenal Therapeutics is -1.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCadrenal Therapeutics has a P/B Ratio of 0.76. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Cadrenal Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here About Cadrenal Therapeutics Stock (NASDAQ:CVKD)Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.Read More CVKD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CVKD Stock News HeadlinesJuly 17, 2024 | prnewswire.comCadrenal Therapeutics to Present at the Emerging Growth Conference on July 18, 2024June 11, 2024 | prnewswire.comCadrenal Therapeutics to Present at the Emerging Growth Conference on June 12, 2024July 27, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.June 3, 2024 | prnewswire.comCadrenal Therapeutics Highlights Presentation of New Trial Data at ISHLT Conference Demonstrating the Importance of Anticoagulation Quality in LVAD PatientsMay 23, 2024 | prnewswire.comCadrenal Therapeutics to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024May 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Cadrenal Therapeutics on Strong Clinical and Financial ProspectsMay 9, 2024 | prnewswire.comCadrenal Therapeutics Provides First Quarter 2024 Corporate UpdateApril 20, 2024 | finance.yahoo.comFavourable Signals For Cadrenal Therapeutics: Numerous Insiders Acquired StockJuly 27, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.April 11, 2024 | finance.yahoo.comCadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024April 11, 2024 | prnewswire.comCadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024April 11, 2024 | marketwatch.comCadrenal Therapeutics Gets FDA Orphan Drug Designation for TecarfarinApril 9, 2024 | markets.businessinsider.comCadrenal Therapeutics: FDA Grants Orphan Drug Designation For Tecarfarin; Stock JumpsApril 9, 2024 | bizjournals.comPonte Vedra-based Cadrenal Therapeutics receives second FDA orphan drug designationApril 9, 2024 | prnewswire.comCadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial HeartsMarch 14, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Cadrenal Therapeutics, Inc. (CVKD), Protara Therapeutics (TARA) and Spruce Biosciences (SPRB)March 11, 2024 | finanznachrichten.deCadrenal Therapeutics, Inc.: Cadrenal Therapeutics Provides Fourth Quarter 2023 Corporate UpdateMarch 11, 2024 | finance.yahoo.comCadrenal Therapeutics Provides Fourth Quarter 2023 Corporate UpdateSee More Headlines Receive CVKD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cadrenal Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CVKD CUSIPN/A CIK1937993 Webwww.cadrenal.com Phone904-300-0701FaxN/AEmployees4Year FoundedN/APrice Target and Rating Average Stock Price Target$3.50 High Stock Price Target$4.00 Low Stock Price Target$3.00 Potential Upside/Downside+683.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.31) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,360,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-75.11% Return on Assets-68.16% Debt Debt-to-Equity RatioN/A Current Ratio8.21 Quick Ratio8.21 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.59 per share Price / Book0.76Miscellaneous Outstanding Shares16,010,000Free Float8,225,000Market Cap$7.15 million OptionableNot Optionable Beta1.69 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for August 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Quang X. Pham (Age 59)Chairman & CEO Comp: $967kMr. Matthew K. Szot CPA (Age 50)CPA, Chief Financial Officer Comp: $594.89kDr. Douglas W. Losordo FACC (Age 66)FAHA, M.D., Chief Medical Officer Comp: $528.69kMr. Jeffrey ColeChief Operating OfficerKey CompetitorsBolt BiotherapeuticsNASDAQ:BOLTEnlivex TherapeuticsNASDAQ:ENLVLisata TherapeuticsNASDAQ:LSTANanoViricidesNYSE:NNVCAcasti PharmaNASDAQ:ACSTView All CompetitorsInsidersJohn Raymond MurphyBought 17,331 shares on 10/4/2023Total: $12,131.70 ($0.70/share)Quang X PhamBought 70,000 shares on 9/1/2023Total: $63,700.00 ($0.91/share)View All Insider Transactions CVKD Stock Analysis - Frequently Asked Questions How have CVKD shares performed this year? Cadrenal Therapeutics' stock was trading at $0.7399 at the beginning of 2024. Since then, CVKD shares have decreased by 39.6% and is now trading at $0.4468. View the best growth stocks for 2024 here. How were Cadrenal Therapeutics' earnings last quarter? Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) posted its quarterly earnings data on Thursday, May, 9th. The company reported ($0.10) earnings per share for the quarter, missing analysts' consensus estimates of ($0.07) by $0.03. When did Cadrenal Therapeutics IPO? Cadrenal Therapeutics (CVKD) raised $7 million in an initial public offering (IPO) on Friday, January 20th 2023. The company issued 1,400,000 shares at $5.00 per share. How do I buy shares of Cadrenal Therapeutics? Shares of CVKD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CVKD) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored4 Steps to Survive the Coming Market CrashCracks threaten us with a widespread collapse unlike anything we've seen in our lifetime. During this prese...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cadrenal Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cadrenal Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
